Message the company or request a 1:1 meeting here.
Filtricine, Inc. is a clinical stage biotechnology company founded on the basis of a nutrient modulation platform for identifying metabolic vulnerabilities in cancer and other diseases. Our technology termed Targeted Nutrients Deprivation (TND) is a method to deplete from the bloodstream nutrients specifically required by cancer cells but not by normal cells. Our first product is a food product – a suite of complete replacement meals that lack several cancer-promoting nutrients. Filtricine has started its first clinical trial of the TND diet in prostate cancer patients at Stanford University Medical Center.